Torrent Pharma collaborates with Boehringer Ingelheim India to co-market its anti-diabetic drug, its fixed dose combinations in India

Empagliflozin is a novel sodium-glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus. Empagliflozin is also indicated to reduce the risk of cardiovascular death, in adults with type 2 diabetes mellitus and established cardiovascular disease. Further, empagliflozin is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure, in adults with heart failure.

As per International Diabetes Federation, India has the second largest diabetes patient base in the world with an estimated 74.2 million adults (20-79 years age group) as of 2021. This is expected to increase to almost 125 million patients by 2045. According to AWACS MAT October 2022 data, the Indian diabetes medications market is valued at INR 16,516 crore, growing at 8.6% CAGR over the last 4 years. The market for SGLT-2 Inhibitors is valued at 1,927 Crores and the SGLT-2 Inhibitors are growing faster than the diabetes market faster at 33% CAGR over the same time period.

Aman Mehta, Director, Torrent Pharmaceuticals Ltd. said, "Torrent is delighted to enter into a strategic partnership with Boehringer Ingelheim India to address the dual challenges of type-2 diabetes and heart failure (both preserved and reduced ejection fractions) in India. I am confident that the launch of Cospiaq, Cospiaq Met and Xilingio will further strengthen our overall Diabetes and Cardiovascular portfolios and bolster our position as a leading player in these high growth segments within the Indian Pharmaceutical Market."

Vani Manja, Managing Director, Boehringer Ingelheim India said, "We are pleased to partner with Torrent for the sales and co-marketing of Empagliflozin and its combinations. Our collaboration with Torrent reaffirms our commitment towards enabling improved access to innovative medicine in India. We believe that the coming together of the healthcare ecosystem is key to address unmet needs of patients."